The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis
Open accessAbstract
BACKGROUND: Methotrexate and cyclosporine are well-known systemic therapies for moderate-to-severe chronic plaque psoriasis. We conducted a randomized, controlled trial comparing methotrexate and cyclosporine in terms of effectiveness, side effects, and the quality of life. METHODS: A total of 88 patients with moderate-to-severe psoriasis were randomly assigned to treatment for 16 weeks with either methotrexate (44 patients; initial dose, 15 mg per week) or cyclosporine (44 patients; initial dose, 3 mg per kilogram of body weight per day) and were followed for another 36 weeks. The primary outcome was the difference between groups in the psoriasis area-and-severity index after 16 weeks of treatment, after adjustment for base-line values; scores were determined in a blinded fashion by trained observers. RESULTS: Two patients were excluded from the analysis after randomization because they were found to be ineligible, and one patient withdrew his consent. Twelve patients in the methotrexate group had to discontinue treatment because of reversible elevations in liver-enzyme levels, and 1 patient in the cyclosporine group had to do so because of an elevation in the bilirubin level, but all 13 were included in the analysis. After 16 weeks of treatment, the mean (+/-SE) score for the psoriasis area-and-severity index decreased from 13.4+/-3.6 at base line to 5.0+/-0.7 among 43 patients treated with methotrexate, whereas the score decreased from 14.0+/-6.6 to 3.8+/-0.5 among 42 patients treated with cyclosporine. After adjustment for base-line values, the mean absolute difference in values at 16 weeks was 1.3 (95 percent confidence interval, -0.2 to 2.8; P=0.09). The physician's global assessment of the extent of psoriasis, the time to and the rates of remission, and the quality of life were similar in the two groups. CONCLUSIONS: No significant differences in efficacy were found between methotrexate and cyclosporine for the treatment of moderate-to-severe psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Aaronson, N. K., Muller, M., Cohen, P. D. A., Essink-Bot, M.-L., Fekkes, M., Sanderman, R., Sprangers, M. A. G., te Velde, A., & Verrips, E. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00097-3 · Cited by 2,276
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Van Ede, A. E., Laan, R. F. J. M., Rood, M. J., Huizinga, T. W. J., Van De Laar, M. A. F. J., Denderen, C. J. V., Westgeest, T. A. A., Romme, T. C., De Rooij, D.-J. R. A. M., Jacobs, M. J. M., et al. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1515::aid-art273>3.0.co;2-7 · Cited by 401
Methotrexate in psoriasis: Revised guidelines
Roenigk, H. H., Auerbach, R., Maibach, H. I., & Weinstein, G. D. (1988) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(88)80237-8 · Cited by 357
Shea, B., Swinden, M. V., Tanjong Ghogomu, E., Ortiz, Z., Katchamart, W., Rader, T., Bombardier, C., Wells, G. A., & Tugwell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000951.pub2 · Cited by 347
Methotrexate for psoriasis. A new therapeutic schedule
Weinstein, G. D. (1971) · Archives of Dermatology · doi:10.1001/archderm.103.1.33 · Cited by 268
Treatment of psoriasis. Part 1. Topical therapy and phototherapy
Lebwohl, M., & Ali, S. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.117046 · Cited by 235
Treatment of psoriasis. Part 2. Systemic therapies
Lebwohl, M., & Ali, S. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.117047 · Cited by 199
Cited by
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Schön, M. P., & Boehncke, W.-H. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041320 · Cited by 955
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Guidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 769
Pathirana, D., Ormerod, A., Saiag, P., Smith, C., Spuls, P., Nast, A., Barker, J., Bos, J., Burmester, G., Chimenti, S., et al. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03389.x · Cited by 703
Self-citationPapp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Lebwohl, M., Tyring, S. K., Hamilton, T. K., Toth, D., Glazer, S., Tawfik, N. H., Walicke, P., Dummer, W., Wang, X., Garovoy, M. R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030002 · Cited by 570
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 558
Gordon, K. B., Langley, R. G., Leonardi, C., Toth, D., Menter, M. A., Kang, S., Heffernan, M., Miller, B., Hamlin, R., Lim, L., et al. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.05.027 · Cited by 510
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A., Koo, J. Y. M., Lebwohl, M., Leonardi, C. L., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.055 · Cited by 460
Gossec, L., Smolen, J. S., Gaujoux-Viala, C., Ash, Z., Marzo-Ortega, H., van der Heijde, D., FitzGerald, O., Aletaha, D., Balint, P., Boumpas, D., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200350 · Cited by 446
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
The Inflammatory Response in Psoriasis: a Comprehensive Review
Deng, Y., Chang, C., & Lu, Q. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8535-x · Cited by 416
Quality of life in patients with psoriasis
Bhosle, M. J., Kulkarni, A., Feldman, S. R., & Balkrishnan, R. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-35 · Cited by 377
Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference
Kalb, R. E., Strober, B., Weinstein, G., & Lebwohl, M. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.11.906 · Cited by 368
Current and future management of psoriasis
Menter, A., & Griffiths, C. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61129-5 · Cited by 321
Gisondi, P., Del Giglio, M., Di Francesco, V., Zamboni, M., & Girolomoni, G. (2008) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26427 · Cited by 307
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., Betts, K. A., & Augustin, M. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.4029 · Cited by 294
S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update
Nast, A., Boehncke, W., Mrowietz, U., Ockenfels, H., Philipp, S., Reich, K., Rosenbach, T., Sammain, A., Schlaeger, M., Sebastian, M., et al. (2012) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07919.x · Cited by 272
Current knowledge on psoriasis and autoimmune diseases
McCormick, T., Ayala-Fontanez, N., & Soler, D. (2016) · Psoriasis: Targets and Therapy · doi:10.2147/ptt.s64950 · Cited by 266
Langley, R. G. B., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.865009 · Cited by 264
Psoralen and Ultraviolet A Light Therapy for Psoriasis
Stern, R. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmct072317 · Cited by 149
Wan, J., Abuabara, K., Troxel, A. B., Shin, D. B., Van Voorhees, A. S., Bebo, B. F., Krueger, G. G., Callis Duffin, K., & Gelfand, J. M. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.03.012 · Cited by 41
An appraisal of the Carlisle-Stouffer-Fisher method for assessing study data integrity and fraud
Mascha, E. J., Vetter, T. R., & Pittet, J.-F. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002415 · Cited by 30
Metadata
- Authors
- Heydendael, V. M. R., Spuls, P. I., Opmeer, B. C., de Borgie, C. A. J. M., Reitsma, J. B., Goldschmidt, W. F. M., Bossuyt, P. M. M., Bos, J. D., & de Rie, M. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-14
- Volume
- 349
- Issue
- 7
- Pages
- 658-665
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1996773947
- Cited by
- 475
- References
- 16
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.